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Abstract 
Benzodiazepines are regularly prescribed for the treatment of anxiety though there are side 
effects. Flavonoids have selective affinity for GABAA receptors implicated in anxiolytic-like 
activity in rodents, but are devoid of the unwanted side effects of benzodiazepines. In this study, 
6-methoxyflavanone (6-MeOF), a positive allosteric modulator of γ-amino butyric acid (GABA) 
responses at human recombinant GABAA receptors, was evaluated for its behavioral profile in 
the elevated plus-maze, as well as the staircase- and open-field tests in mice. In addition, the 
distribution of 6-MeOF in selected brain areas involved in anxiety (amygdala and cerebral 
cortex) was also examined using a validated high performance liquid chromatography/ultraviolet 
detection (HPLC/UV) method. 6-MeOF (10, 30 and 50 mg/kg) exerted an anxiolytic-like effect, 
increasing entries and time spent in the open arm and the central platform, as well as head-
dipping frequency in the mouse elevated plus-maze assay. It also decreased rearing incidence 
without suppressing the number of steps ascended in the staircase test. Whereas, in the open-field 
anxiety test, 6-MeOF had no effect on locomotor activity at lower doses, a decrease was 
observed at the highest dose (100 mg/kg). 6-MeOF additionally produced an anxiolytic-like 
increase in the time spent at the center of the open-field apparatus. These effects were 
preferentially antagonized by pentylenetetrazole (15 mg/kg). Furthermore, pharmacokinetic 
studies disclosed a rapid appearance of 6-MeOF in the plasma and discrete brain areas. Taken 
together, our findings suggest that 6-MeOF readily crosses the blood brain barrier (BBB) 
generating anxiolytic activity, mediated through the GABAergic system. 
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1. Introduction 
Generalized anxiety disorder, social anxiety and panic disorder have long been recognized as 
being amongst the most commonplace disabling conditions in society (Association, 1994). 
Although selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake 
inhibitors (SNRIs) are considered as primary treatments for anxiety, benzodiazepines are still 
quite regularly prescribed despite having unwanted side effects (Davidson, 2009; Paladini et al., 
1999). Benzodiazepines act as positive allosteric modulators via a subpopulation of γ-amino 
butyric acid receptors (GABAA) increasing the frequency of chloride channel opening (Chebib 
and Johnston, 2000). In the brain, GABA tends to be the most abundant inhibitory 
neurotransmitter regulating different physiological phenomena including sleep, anxiety, memory 
formation and reward (Zeilhofer et al., 2009) and GABAA receptors are implicated as a major 
inhibitory element (Macdonald and Olsen, 1994). Accordingly, GABA inhibitory interneurons 
function via GABAA receptor subtypes that are involved in mediating behavior (Mohler et al., 
2004).  
A few years ago, a new family of ligands possessing a flavonoid nucleus, was unveiled by a 
research group in a quest for safer GABAA receptor modulators (Ognibene et al., 2008). These 
polyphenolic compounds (phenyl benzopyrones) have been found not only in plants, but also in 
dietary components and they have been produced synthetically as well (Kempuraj et al., 2005). 
Flavonoids have been extensively examined for their peripheral actions, however, a selective 
affinity for GABAA receptors has been reported in studies using rat and bovine brain membrane 
binding assays (Hong and Hopfinger, 2003). In conjunction with binding studies, behavioral 
investigations have also disclosed anxiolytic-like activity of flavonoids in rodents without 
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unwanted benzodiazepine side effects (Griebel et al., 1999). Furthermore, a number of synthetic 
derivatives of natural flavonoids are known for their potent anxiolytic properties (Karim et al., 
2011; Fernandez et al., 2008; Griebel et al., 1999). 
Interestingly, a recent radioligand binding study of 6-MeOF (a synthetic flavanone, Fig. 1) has 
revealed that its molecular binding site is different from other known flavonoid modulators of 
GABAA receptors. Thus, it binds to a novel allosteric site independent of both high and low 
affinity benzodiazepine binding sites (Hall et al., 2014). Consequently, it acts upon γ-subunit 
containing GABAA receptors like diazepam, but is insensitive to flumazenil antagonism whilst 
inhibiting [
3
H]-flunitrazepam binding at the same time. Hence, 6-MeOF as a GABAA receptor 
ligand, may conceivably exhibit an anxiolytic profile. Therefore, this study was devised to 
investigate such a propensity of activity in vivo utilizing different anxiety models. We also 
investigated the possible contribution of GABAergic mechanisms to the pharmacological activity 
of 6-MeOF by pretreatment with a designated GABAA antagonist, pentylenetetrazole (Rattka et 
al., 2011). Additionally, high performance liquid chromatography (HPLC) coupled with UV 
detection was employed to determine the pharmacokinetic profile as well as the distribution 
pattern of 6-MeOF both in plasma and the brain areas (cerebral cortex and amygdala) involved in 
anxiety. 
2. Materials and methods 
2.1. Drugs and chemicals 
6-Methoxyflavanone (>95%, Sigma-Aldrich, USA), HPLC grade acetonitrile (99.9%) as well as 
methanol (99.9%) (Fisher Scientific, UK), diazepam (Valium, 10 mg/2 mL, Roche, Pakistan) and 
pentylenetetrazole (≥98%, Sigma Aldrich, UK) were employed. 6-MeOF was dissolved in a 
vehicle comprising of Tween 80 (1%), DMSO (5%) and saline (94%). 
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2.2. Animals 
BALB/c mice (18-30 g) of both sex (equal numbers of males and females per group), bred and 
maintained in a controlled environment (temperature = 22 ± 2º C and relative humidity = 60 ± 
10%) on a 12:12 h day/night cycle (lights on at 7:00 am) in the animal house (Department of 
Pharmacy, University of Peshawar) were used. Food and water were provided ad libitum and 
both males as well females were included experimentally because previous studies have verified 
that mice of either sex may be employed in measures of anxiety (File, 2001). All experiments 
were performed in accordance with the UK Animals (Scientific Procedures) Act 1986 and 
according to the rules and ethics set forth by the Ethical Committee of the Department of 
Pharmacy, University of Peshawar. Approval for this study was granted with the registration 
number: 08/EC-15/Pharm (dated: April 10, 2015). 
2.3. Behavioral analysis 
Mice were housed in polycarbonate cages in groups of three per cage (dimensions 42.5 × 26.6 × 
15.5 cm). All the behavioral tests were performed during the light phase between 8:00 am to 2:00 
pm. On the test day, the mice were transferred to a dimly illuminated room (red light, 40 lux) 1 h 
prior to experimentation. Each experiment was performed on separate groups of animals (n = 6) 
according to the guidelines of Animal (Scientific Procedures) Act 1986. The sample size was 
calculated according to the resource equation method (Festing and Altman, 2002). There are no 
previous reports on the pharmacological activity of 6-MeOF, so the dose range selected (10–100 
mg/kg) was based on those of other synthetic flavonoids known to exert anxiolytic activity 
(Karim et al., 2011; Ognibene et al., 2008). Diazepam is widely used in the dose range 1.0–3.0 
mg/kg as a standard in different anxiety tests, therefore 2.0 mg/kg was selected as mid-range 
(Karim et al., 2011; Fernandez et al., 2009). PTZ is considered non-convulsive and anxiogenic at 
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doses lower than 30 mg/kg, so a 15 mg/kg dose was selected for the purpose of the current study 
(Hoeller et al., 2013; Rodgers et al., 1995). 
2.4. Elevated plus-maze 
The apparatus was comprised of two open arms (27 × 5 × 0.25 cm) and two closed arms (27 × 5 
× 15 cm) extended from a central platform (5 × 5 cm) at a height of 40 cm above floor level 
(Macri et al., 2002). The animals were habituated in a dimly illuminated laboratory (red light, 40 
lux) 1 h prior to testing. The mice were then placed on the intersection of the open and closed 
arms facing the open arm, 20 min post-treatment with vehicle, diazepam (2.0 mg/kg; i.p.) or 6-
MeOF (10, 30, 50 and 100 mg/kg; i.p.). They were allowed to freely explore the maze for 5 min. 
All the experimental sessions were recorded with a digital camera (Cat’s Eye IR IP Camera, 
Taiwan). Parameters including the percentage of entries and time spent in open arms 
(entries/time spent in open arms/ total entries/time × 100), time spent at the intersection/center of 
the apparatus (s) and closed arm entries (animal entry with all the four paws into either closed 
arm) were considered as spatio-temporal. Other parameters incorporating head-dipping 
frequency (depressing head-shoulders at the edges of maze) and the frequency of rearing were 
considered under ethological measures (Rodgers et al., 1995; Pellow et al., 1985). In the drug 
combination study, PTZ (15 mg/kg; i.p.) was administered 30 min prior to drug administration. 
After each trial the apparatus was thoroughly swabbed with a wet paper towel (soaked in a 
mixture of ethanol, detergent and water) in order to remove any odor or residues (Karim et al., 
2011). 
2.5. Staircase test 
Mice (18-24 g) were administered vehicle, 6-MeOF (10, 30, 50 and 100 mg/kg; i.p.) or diazepam 
(2.0 mg/kg; i.p.). In the drug combination experiments, PTZ (15 mg/kg; i.p.) was administered 
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30 min prior to drug treatment. Thirty min later, the number of steps ascended and rears by each 
animal were observed for 3 min using the staircase apparatus according to the methods described 
by Simiand and coworkers (1984). A step was considered to be ascended only if the criterion 
was met whereby an animal placed all four paws on the step. 
 
2.6. Open-field test 
Locomotor activity was evaluated in a box with dimensions of 50 × 40 cm, and divided into four 
equal quadrants by lines. Mice (22 ± 2 g) were administered 6-MeOF (10, 30, 50 and 100 mg/kg; 
i.p.) or diazepam (2.0 mg/kg; i.p.). In the drug combination experiments, PTZ (15 mg/kg; i.p.) 
was administered 30 min prior to drug treatment. Thirty min later, the animals were placed at the 
center of the recording apparatus and the number of lines crossed and time spent at the center of 
the apparatus by each animal was recorded for 5 min using a digital camera (Cat’s Eye IR IP 
Camera, Taiwan) (Hall, 1934). 
2.7. Pharmacokinetic profile of 6-methoxyflavanone 
6-MeOF was analyzed in plasma and selected brain areas including cerebral cortex and 
amygdala. The cerebral cortex and amygdala were selected because of their evident role in 
modulating anxiety (LeDoux, 2003; Davis, 1992). Mice (25-30 g) were administered an i.p. dose 
of 6-MeOF (30 mg/kg) and the plasma along with selected brain areas were collected after 15, 
30, 45, 60 and 120 min post-administration (n = 6 each for different time periods). The 
HPLC/UV method used for the determination of 6-MeOF in the plasma and brain was highly 
reproducible and validated with respect to accuracy, precision, linearity, sensitivity and stability 
(Akbar et al., 2016). 
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2.7.1. Extraction procedure 
For plasma samples, the collected blood was centrifuged (K240R, Centurion Scientific, UK) for 
10 min and the supernatant obtained was mixed with 200 µl of HPLC grade methanol (extraction 
solvent) and vortex mixed (Gyromixer, Parkland Scientific Production, Pakistan) for 20 s. The 
sample was then centrifuged at 16,000 × g for 5 min followed by drying of the supernatant with 
nitrogen. The analyte was reconstituted with the mobile phase and 20 µl of sample was then 
injected directly into the HPLC/UV system (Xie et al., 2004). Selected brain areas were excised, 
weighed and homogenized (Wise stir HS 30E) in HPLC grade methanol (200 µl) at 2012.4 × g. 
The samples were then centrifuged at 12000 × g for 20 min and filtered through a 0.45 μm filter. 
The analyte obtained was dried by nitrogen evaporation and reconstituted with 200 µl mobile 
phase.  The resulting sample was injected (20 µl) into the HPLC/UV system (de Rijke et al., 
2006). 
2.7.2. Analytical method 
The HPLC system was operated at 30º C and consisted of double pumps (LC-20AT Shimadzu, 
Japan) coupled to a UV detector (SPD-20A Shimadzu, Japan) and column (Purospher C18, 250 
mm × 4.6 mm × 5 μm particle size). The mobile phase was prepared by mixing few drops of 1% 
TEA (triethylamine) in methanol and water at a ratio of 75:25 v/v, sonicated for 15 min and 
filtered under vacuum through a 0.45 μm filter paper. The system flow rate was adjusted to 1.0 
ml/min and the wavelength of the detector set at 240 nm, the peak of 6-MeOF being obtained 
within a runtime of 9 min. The peaks for different samples were confirmed by spiking them with 
standard 6-MeOF. 
The pharmacokinetic parameters were estimated by a non-compartmental method using 
pharmacokinetic solutions 2.0 software package (Summit research services, Pharmacokinetics 
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and metabolism software 68911 open field Dr. Mantrose, CO 81401, USA). 
2.8. Statistical analysis  
Data were expressed as mean ± S.E.M. or S.D. One way ANOVA with post hoc Dunnett’s test 
was employed, while two-factor independent ANOVA was applied in the drug combination 
studies using GraphPad Prism 5 (GraphPad Software Inc. San Diego CA, USA). 
 
3. Results 
3.1. Elevated plus-maze 
3.1.1. Spatio-temporal parameters 
Interestingly, the profile of activity exhibited by diazepam (2.0 mg/kg, P ˂ 0.001) with regard to 
open arm entries by mice was comparable to that of 6-MeOF. Consequently, 6-MeOF [(10 
mg/kg, P ˂ 0.05), (30 mg/kg, P ˂ 0.001) and (50 mg/kg, P ˂ 0.001)] significantly increased the 
open arm entries in a dose-dependent manner, as compared to the vehicle [F(5,30) = 20.98, P ˂ 
0.0001]. However, this parameter was decreased by the higher dose of 100 mg/kg (Fig. 2A). 
Similarly, the percentage of time spent in the open arms was substantially increased by 6-MeOF 
(30 mg/kg, P ˂ 0.001 and 50 mg/kg, P ˂ 0.001) [F(5,30) = 16.94, P ˂ 0.0001] (Fig. 2B). Likewise, 
the time spent on the central platform was also increased by 6-MeOF in a dose-dependent 
manner, in comparison with the vehicle treated group (30 mg/kg, P ˂ 0.01 and 50 mg/kg, P ˂ 
0.001) [F(5,30) = 26.21, P ˂ 0.0001] (Fig. 2D). Moreover, the number of closed arm entries was 
not affected by 6-MeOF, suggesting that there was no effect on general locomotor activity (Fig. 
2C) [F(5,30) = 1.055, P ˂ 0.404]. In the drug combination studies, pretreatment with PTZ (15 
mg/kg) significantly prevented the increase promoted by 6-MeOF (30 mg/kg) in the entries 
[F(1,30) = 76.60, P ˂ 0.0001 for pretreatment; F(5,30) = 20.98, P ˂ 0.0001 for treatment and F(1,30) = 
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10.69, P ˂ 0.0001 for interaction] and time spent in the open arms [F(1,30) = 88.64, P ˂ 0.0001 for 
pretreatment; F(5,30) = 16.94, P ˂ 0.0001 for treatment and F(1,30) = 2.21, P ˂ 0.0001 for 
interaction] as shown in Fig. 5A.  
3.1.2. Ethological parameters 
Diazepam (2.0 mg/kg, P ˂ 0.001) and 6-MeOF (at dose of 50 mg/kg, P ˂ 0.001) significantly 
increased the frequency of wall-rearing in mice as compared to the vehicle control (Fig. 3A) 
[F(5,30) = 11.66, P ˂ 0.0001]. Similarly, a significant [F(5,30) = 29.25, P ˂ 0.0001] increase in the 
frequency of unprotected head-dipping was displayed by mice treated with either diazepam (2.0 
mg/kg, P ˂ 0.001) or 6-MeOF [(30 mg/kg, P ˂ 0.001) and (50 mg/kg, P ˂ 0.001)] as compared 
to the vehicle treated group (Fig. 3B). 
3.2. Staircase test 
As shown in Fig. 4B, 6-MeOF dose-dependently (10 mg/kg, P ˂ 0.05; 30 mg/kg, P ˂ 0.001; 50 
mg/kg, P ˂ 0.001 and 100 mg/kg, P ˂ 0.001) decreased the number of rearing episodes 
compared to the vehicle control group [F(5,30) = 16.01, P ˂ 0.0001]. In contrast, there was 
biphasic response in the staircase test. Thus, 6-MeOF augmented (10 mg/kg, P ˂ 0.05 and 30 
mg/kg, P ˂ 0.001) the number of steps ascended when compared to vehicle control (Fig. 4A) 
[F(5,30) = 32.09, P ˂ 0.0001] but decreased ascended step numbers at higher doses, attaining 
statistical significance (P ˂ 0.001) at 100 mg/kg. In the drug combination studies, pretreatment 
with PTZ (15 mg/kg) significantly prevented the decrease induced by 6-MeOF (30 mg/kg) in the 
number of rears [F(1,30) = 28.50, P ˂ 0.0001 for pretreatment; F(5,30) = 16.01, P ˂ 0.0001 for 
treatment and F(1,30) = 9.96, P = 0.0949 for interaction] and the increase in number of steps 
ascended [F(1,30) = 49.78, P ˂ 0.0001 for pretreatment; F(5,30) = 32.09, P ˂ 0.0001 for treatment 
and F(1,30) = 19.52, P ˂ 0.0001 for interaction] as shown in Fig. 5B.  
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3.3. Open-field test 
The locomotor activity of the animal group treated with diazepam (2.0 mg/kg) or 6-MeOF (10, 
30, 50 and 100 mg/kg) was compared with those administered vehicle in the open-field test. 6-
MeOF at lower doses (10, 30 and 50 mg/kg) had no significant effect on locomotion, however, it 
dose-dependently [F(5.30)= 37.69, P˂ 0.0001] increased the time spent at the center of the 
apparatus (10 mg/kg, P ˂ 0.01; 30 mg/kg, P ˂ 0.001 and 50 mg/kg, P ˂ 0.001), when compared 
to vehicle control. In contrast, diazepam (2.0 mg/kg, P ˂ 0.001) and highest dose of 6-MeOF 
(100 mg/kg, P ˂ 0.001) [F(5,30) = 12.61, P˂ 0.0001] notably decreased locomotor activity and the 
time spent at center of the apparatus (Fig. 6). Pretreatment with PTZ (15 mg/kg) did not  modify 
the locomotor activity but significantly decreased the promoted time spent at the center of the 
apparatus by 6-MeOF (30 mg/kg, P ˂ 0.05) [F(1,30) = 72.71, P ˂ 0.0001 for pretreatment; F(5,30) = 
37.69, P ˂ 0.0001 for treatment and F(1,30) = 5.97, P = 0.0014 for interaction]  (Fig. 7). 
3.4. Pharmacokinetic profile of 6-methoxyflavanone 
The area-specific distribution of 6-MeOF in plasma and selected brain areas including the 
cerebral cortex and amygdala were analyzed. The highest concentration of 6-MeOF was 
observed in plasma (2.51 ± 1.65 µg/ml) followed by the amygdala (0.73 ± 0.07 µg/g) and 
cerebral cortex (0.70 ± 0.04 µg/g) 30 min after administration. These concentrations declined 
rapidly with time, falling below the limit of detection after 120 min in plasma and 60 min in the 
discrete brain areas as shown in Fig. 8. The pharmacokinetic parameters in Table 1 further verify 
that 6-MeOF quickly appeared in the systemic circulation with a Tmax of 30 min and the T1/2, Cmax 
and AUC values being 46.23 ± 16.2 min, 2.7233 ± 1.5812 µg/ml and 62.982 ± 25.272 µg ml/min 
respectively. This was in contrast to the maximal level of 6-MeOF observed in the amygdala 
(AUC of 30 ± 0.083 µg g/min) compared to other brain areas. 
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4. Discussion 
Anxiety-related disorders frequently require a pharmacological approach as a first-line treatment, 
although a number of unwanted side effects accompany the currently available therapeutic 
options. Accordingly, the demand for substitute pharmacological agents is mounting. The aim of 
the present study was to evaluate the behavioral profile of 6-MeOF in mice utilizing different 
anxiety tests. The elevated plus-maze is a validated test for the assessment of anxiety in rodents, 
especially while addressing benzodiazepine-induced anxiolysis. This method may be employed 
not only for evaluating anxiolytic but also anxiogenic effects of pharmacological agents in 
rodents (Pellow et al., 1985). Mice invariably prefer location within the closed arms avoiding the 
unprotected open arms due to fear related anxiety associated with exposure plus the elevation of 
the apparatus above the floor (Fernandes and File, 1996). With regard to spatio-temporal 
measures, the treated mice (6-MeOF and diazepam) spent appreciably longer in the open arms 
and on the central platform of the apparatus. The number of open arm entries was raised at the 
same time, implicating an anxiolytic-like effect of both 6-MeOF and diazepam. The vehicle 
treated mice, by way of contrast, showed preference for the closed arms and spent less time on 
the central platform of the apparatus. Usually, less time spent at the intersection/central platform 
is thought to be an index of more anxious behavior (Carola et al., 2002). Whereas, the mice 
treated with 6-MeOF (10, 30 and 50 mg/kg) exhibited an anxiolytic profile analogous to that of 
the diazepam treated mice. A novel environment is often coupled with a notable degree of 
anxiety that is evaluated by measuring the entries and time spent in the open arms (unprotected). 
Agents that augment these measures are considered to be anxiolytic, while those that reduce 
them are regarded as anxiogenic in nature (Macri et al., 2002; Rodgers et al., 1995; Pellow et al., 
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1985). Similarly, the ethological parameters representing the anxiolytic-like behavior of 6-
MeOF, in raising the frequency of unprotected head-dipping and wall-rearing were comparable 
to diazepam. In the context of this finding, an increased head-dipping frequency in mice is 
associated with low anxiety levels (Rodgers et al., 1995).  
6-MeOF significantly reduced the number of rears in a dose-dependent manner without reducing 
the number of steps ascended in the staircase test. In light of this, GABAA receptors mediate 
rearing in the staircase test and anxiolytic agents are reported to decrease rearing without altering 
the number of steps ascended (Emmanouil and Quock, 1990). This effect was blocked by 
flumazenil that proved to be inactive alone. Non-benzodiazepines (such as buspirone and 
tricyclic antidepressants) are known to suppress both the rearing and number of steps ascended, 
while GABAA-benzodiazepine receptor agonists display a dissociation between these two 
measures i.e. they suppress rearing but do not affect the number of steps ascended (Belzung et 
al., 1988; Pollard and Howard, 1986). This dissociated effect was also observed in our study. In 
the staircase test, diazepam and 6-MeOF (10 and 30 mg/kg) both reduced the incidence of 
rearing without decreasing the number of steps ascended.  However at the higher dose of 100 
mg/kg, 6-MeOF significantly reduced both measures and this high dose effect was probably 
derived from an α1-subunit containing GABAA receptor mediated sedative action of the 
flavanone (Hall et al., 2014; Rudolph et al., 1999).  
Ambulatory locomotor activity was assessed in the open-field test which has been designated as 
a model of normal anxiety since it is susceptible to the anxiolytic-like activity of 
benzodiazepines in rodents (Prut and Belzung, 2003). Mice with elevated alertness exhibit 
increased locomotion and conversely, a mobility decline is associated with the onset of sedation 
(Yadav et al., 2008). 6-MeOF did not modify locomotor activity at an anxiolytic dose level. 
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However, at the highest dose (100 mg/kg), it markedly reduced locomotor activity in a similar 
fashion to diazepam. Furthermore, an increase in the time spent in the central location of the 
open field arena was observed in the 6-MeOF (10, 30 and 50 mg/kg) treated as opposed to the 
vehicle treated animals. This is an anxiolytic-like response since mice typically display 
thigmotaxis by preferring peripheral arena positioning (Prut and Belzung, 2003). It is important 
to note that 6-MeOF exhibited sedative-depressant actions only at doses at least two to three fold 
higher than those producing anxiolytic-like effects. Hence, in comparison to diazepam, which 
has an implicit overlap of doses producing therapeutic and unwanted side effects, 6-MeOF 
ameliorates anxiety at doses well-below those inducing sedation. 
6-MeOF induced anxiolytic-like effects at lower doses (30 and 50 mg/kg) in the unconditioned 
models of anxiety. In these paradigms, an increase in dose was matched by an increase in 
anxiolytic action. However, at the highest dose employed (i.e. 100 mg/kg), there was a loss of 
anxiolytic activity. In this instance, a depressant effect may well have been associated with α1-
subunit GABA mediated sedative effects of 6-MeOF due to the fact that α1- and α2-subunit 
containing GABAA receptors mediate sedative and anxiolytic activities respectively (Hall et al., 
2014; Rudolph et al., 1999). Various flavonoids have been reported to act either upon the 
benzodiazepine site of GABAA receptors (Möhler et al., 2004; Viola et al., 1995) causing 
sedation or to have minimal depressant activity on the central nervous system (Fernandez et al., 
2008; Viola et al., 1995; Wolfman et al., 1994) without actually inducing any quantifiable 
sedative effects. The low dose (up to 50 mg/kg) anxiolytic-like effect might explain the fact that 
6-MeOF exhibits a much greater efficacy in modulating α2-subunit containing GABAA receptor 
activity, which would appear to induce an anxiolytic action at low receptor occupancy. Thus, the 
selectivity of 6-MeOF for α2-subunit containing GABAA receptors (Hall et al., 2014) along with 
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its in vivo behavioral effects in mice support its application as an anxiolytic agent.  
The position 6 of the flavone nucleus is considered active even without any substitution (Huang 
et al., 2001) and is known for conferring anxiolytic properties to this group, whereas, the 
flavanone nucleus itself is thought to be inactive with regard to anxiolysis (Wang et al., 1999). 
However, recent studies have established that substitution at position 6 on the flavanone nucleus 
augments the anxiolytic properties of this group (Ognibene et al., 2008).  
The biodistribution of 6-MeOF was evaluated in plasma as well as the cerebral cortex and 
amygdala. The pharmacokinetic profile revealed that 6-MeOF had penetrated the blood-brain 
barrier (BBB) because an appreciable concentration level was achieved in these brain regions 30 
min after administration. Various studies on rodents and humans have reported a role of the 
amygdala in processing fear and anxiety-related behaviors (LeDoux, 2003; Gonzalez et al., 1996; 
Sananes and Davis, 1992) and intra-amygdaloid benzodiazepine injections initiate the onset of 
anxiolytic effects (Hodges et al., 1987). Moreover, the amygdala is extensively connected to 
different cerebral cortical regions, especially the medial and orbital zones of the prefrontal 
cortex. In respect of this, GABA afferents of the cerebral cortex synapse in the amygdala, 
providing a crucial inhibitory input to this region (Davis, 1992). Analysis of the pharmacokinetic 
data revealed an increased brain to plasma ratio in the amygdala (Kp= 0.47) followed by the 
cerebral cortex (Kp= 0.37) suggesting that 6-MeOF is readily distributed into these brain areas. 
The in vivo brain to plasma ratio has been extensively utilized as a gold standard method for 
determining the brain uptake of drugs. The normal Kp ratio ranges from -2.00 to +1.00 and drugs 
having a value greater than 0.3 are considered to be readily distributed in the brain (Di et al., 
2008). Thus, 6-MeOF expressed KP ratios in the amygdala and cerebral cortex of an order 
indicating that they not only cross the BBB but also distribute in these brain areas which have 
16 
 
been implicated in anxiety.  
PTZ, a non-selective GABAA receptor modulator known to act upon the picrotoxin site and 
reduce chloride influx (de Carvalho et al., 2011; Fraser et al., 2010), significantly reversed the 
anxiolytic-like effects induced by 6-MeOF in all the anxiety tests employed. However, it lacked 
anxiolytic activity per se in the current study. Moreover, diazepam acts upon the benzodiazepine 
site on the GABAA receptor complex and flumazenil is a selective antagonist at this site which is 
distinct from the picrotoxin site and so PTZ did not  antagonize the effects of diazepam (Huang 
et al., 2001). In vitro studies have also shown that flumazenil does not reverse the GABAA 
receptor modulatory effects of  6-MeOF (Hall et al., 2014) suggesting a different site of action 
for this particular flavanone. PTZ significantly attenuated the anxiolytic effects produced by 6-
MeOF, further implicating an involvement of the GABAergic system. This accords with 
radioligand binding studies that ascertained 6-MeOF as a positive allosteric modulator at 
GABAA receptors with a unique binding site (Hall et al., 2014). Hence, our findings correlate 
with in vitro binding studies and the in vivo behavioral profile of 6-MeOF manifests an 
anxiolytic proclivity. 
5. Conclusion 
The outcome of this study suggests that 6-MeOF penetrates the BBB generating in vivo 
anxiolytic activity, most probably mediated via flumazenil-insensitive PTZ binding sites. 
Therefore 6-MeOF might be employed as a therapeutic option in the treatment of anxiety, though 
clinical and further molecular studies are required to clarify the exact underlying protective 
mechanisms.  
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FIGURE LEGENDS 
 
Fig. 1. Chemical structure of 6-methoxyflavanone (6-MeOF). 
 
Fig. 2. Effect of 6-methoxyflavanone (6-MeOF; 10, 30, 50, and 100 mg/kg) and diazepam (DZ; 
2.0 mg/kg) in mice on (A) the % open arm entries, (B) the % time spent in open arms, (C) the 
number of closed arm entries and (D) the time spent in the center of the apparatus in the elevated 
plus-maze test. 
*
P ˂ 0.05, **P ˂ 0.01, ***P ˂ 0.001 compared to vehicle control (Veh) (ANOVA 
with post hoc Dunnett’s test) (n = 6). 
Fig. 3. Effect of 6-methoxyflavanone (6-MeOF; 10, 30, 50, and 100 mg/kg) and diazepam (DZ; 
2.0 mg/kg) in mice on (A) the wall-rearing frequency and (B) the head-dipping frequency in the 
elevated plus-maze test. 
**
P ˂ 0.01, ***P ˂ 0.001 compared to vehicle control (Veh) (ANOVA 
with post hoc Dunnett’s test) (n = 6). 
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Fig. 4. Effect of 6-methoxyflavanone (6-MeOF; 10, 30, 50, and 100 mg/kg) and diazepam (DZ; 
2.0 mg/kg) in mice on (A) the number of steps ascended and (B) the number of rears in the 
staircase test. 
*
P ˂ 0.05, **P ˂ 0.01, ***P ˂ 0.001 compared to vehicle control (Veh) (ANOVA 
with post hoc Dunnett’s test) (n = 6). 
Fig. 5. Effect in mice on the (A) % entries and time spent in the open arms in the elevated plus- 
maze and (B) number of rears and number of steps ascended in the staircase test, 30 min after i.p. 
treatment with diazepam (DZ-2.0 mg/kg), 6-methoxyflavanone (6-MeOF-30 mg/kg) pretreated 
with pentylenetetrazole (PTZ-15 mg/kg), pentylenetetrazole (PTZ-15 mg/kg) alone or vehicle 
(Veh). Bars represent mean ± S.E.M. Results were analyzed by performing 2-factor independent 
ANOVA among the groups. 
**
P ˂ 0.01, ***P˂ 0.001 compared to diazepam (2.0 mg/kg) alone or 
6-MeOF (30 mg/kg) alone (n = 6).  
 
Fig. 6. Effect of 6-methoxyflavanone (6-MeOF; 10, 30, 50, and 100 mg/kg) and diazepam (DZ; 
2.0 mg/kg) in mice on (A) locomotor activity (number of line crossings) and (B) the time spent at 
the center of apparatus in the open-field test. 
*
P ˂ 0.05, **P ˂ 0.01, ***P ˂ 0.001 compared to 
vehicle control (Veh) (ANOVA with post hoc Dunnett’s test) (n = 6). 
Fig.7. Crossings and time spent at the center of the apparatus 30 min after i.p. treatment with 6-
methoxyflavanone (6-MeOF-30 mg/kg) and diazepam (DZ-2.0 mg/kg) in animals pretreated 
with pentylenetetrazole (PTZ-15 mg/kg); pentylenetetrazole (PTZ-15 mg/kg) alone or vehicle 
(Veh) in the open-field test. Bars represent mean ± S.E.M. 
*
P ˂ 0.05 compared to diazepam (2.0 
mg/kg) alone or 6-MeOF (30 mg/kg) alone (two-way ANOVA) (n = 6).  
Fig. 8. Area-specific distribution of 6-MeOF post administration (30 mg/kg; i.p.) at 15, 30, 45, 
60 and 120 min. 
Fig.9. Chromatograms showing (A) mobile phase spiked with standard 6-MeOF (1 µg/ml), and 
in vivo analyte taken 30 min post administration (30 mg/kg; i.p.) from mice (B) plasma, and (C) 
brain 
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TABLES 
 
 
Table 1. Pharmacokinetic parameters of 6-methoxyflavanone (30 mg/kg; i.p.) observed in the 
plasma and selected brain areas of mice.  
Sample 
Pharmacokinetic parameter 
T1/2 (min) Tmax(min) 
Cmax(µg/ml, 
µg/g) 
AUC (µg 
ml/min, µg 
g/min) 
Plasma 46.23 ± 16.2 30 ± 10.7 2.7233 ± 1.5812 62.982 ± 25.272 
Cerebral cortex 36.15 ± 3.06 30 ± 10.01 0.7 ± 0.008 23.23 ± 0.30 
Amygdala 23.2 ± 0.16 30 ± 0.04 0.7 ± 0.012 30 ± 0.083 
Values are expressed as mean ± S.D. n = 6. 
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